− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...

OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the effectiveness and ...

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Deerfield, Ill., May 20, 2014, and Osaka, Japan, May ...

Please provide your email address to receive an email when new articles are posted on . Entyvio was shown to have low incidence rates of serious infections, infusion-related reactions and malignancies ...

"These data from the VICTORY Consortium highlight the effectiveness of Entyvio in achieving mucosal healing and clinical remission in the real-world, and support the use of Entyvio as a first-line ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

In May, the U.S. Food and Drug Administration (FDA) simultaneously approved Entyvio for the treatment of adults with moderately to severely active UC and CD. That same month, Entyvio was also granted ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...

Studies, presented at the 25th UEG Week, demonstrated the effectiveness of Takeda’s Entyvio in treating ulcerative colitis and Crohn’s disease, IBD News Today reports. From May 2014 to January 2017, ...

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company ...

New clinical study also provides data for Entyvio ® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients OSAKA, Japan, Feb. 16, 2018 /CNW/ - Takeda ...